This once-hot cancer-detection company’s stock got cut in half after a failed trial

MarketWatch Published Updated Stocks
Sign in to save

Affected assets and topics

$NASDAQ NASDAQ

Why it matters

Grail's stock plummeted after a failed trial of its cancer-detection test, making it the Nasdaq's biggest loser, cutting its value in half.

Expected market reaction

Bearish Confidence 90% How confidence is read Horizon: Short term Impact: High

Market impact analysis based on bearish sentiment with 90% confidence.

Evidence trail

Evidence
Source MarketWatch
Claim This once-hot cancer-detection company’s stock got cut in half after a failed trial
Affected assets NASDAQ
AI inference Bearish · 90%
Generated 2026-02-20 21:26

AI provenance

Analysed by Llama 3.1 8B Instant (Groq) Methodology v1.0 Generated
Technical identifiers
Provider tag
groq-llama-3.1-8b-instant
Model id
llama-3.1-8b-instant
Analysis version
groq-llama-3.1-8b-instant
Article id
48352
Timeframe
6h

Prediction lifecycle

  • Llama 3.1 8B Instant (Groq) NASDAQ Bearish 90% 6h
    Generated 6h Verified

    Scored incorrect

Logged at publication, scored automatically once the window closes — never edited.

Actual outcome

Asset NASDAQ
Reference price 22716.13000000
Price at evaluation 23592.11000000
Change 3.8562%
Result Scored incorrect

Original source

Grail’s stock was the Nasdaq’s biggest loser Friday, after a key trial of its Galleri early-detection cancer test failed to meet its primary endpoint.

Read the full article on MarketWatch

Original article published by MarketWatch on February 21, 2026. Analysis and insights provided by AnalystMarkets AI.

More of the NASDAQ narrative

This model on similar stories

Llama 3.1 8B Instant (Groq) · 40.5% correct across 1187 scored calls on indices See the full record